中證網訊(xun)（記者(zhe) 徐金忠）復星醫(yi)藥(yao)8月25日(ri)晚間發(fa)布半(ban)年(nian)報。公(gong)(gong)告顯(xian)示，2020年(nian)上(shang)半(ban)年(nian)，復星醫(yi)藥(yao)實(shi)現(xian)(xian)(xian)營(ying)(ying)業(ye)收(shou)入(ru)140.28億(yi)(yi)元，同(tong)(tong)比(bi)(bi)下降1.02%。其(qi)中：藥(yao)品制造與研發(fa)業(ye)務實(shi)現(xian)(xian)(xian)營(ying)(ying)業(ye)收(shou)入(ru)100.12億(yi)(yi)元，同(tong)(tong)比(bi)(bi)減少(shao)8.11%；醫(yi)療器械(xie)與醫(yi)學診斷(duan)業(ye)務實(shi)現(xian)(xian)(xian)營(ying)(ying)業(ye)收(shou)入(ru)26.41億(yi)(yi)元，同(tong)(tong)比(bi)(bi)增長(chang)46.96%；醫(yi)療服(fu)務業(ye)務實(shi)現(xian)(xian)(xian)營(ying)(ying)業(ye)收(shou)入(ru)13.60億(yi)(yi)元，同(tong)(tong)比(bi)(bi)減少(shao)6.83%。報告期(qi)內，公(gong)(gong)司實(shi)現(xian)(xian)(xian)歸(gui)屬于(yu)(yu)上(shang)市(shi)公(gong)(gong)司股東凈(jing)利潤(run)17.15億(yi)(yi)元，歸(gui)屬于(yu)(yu)上(shang)市(shi)公(gong)(gong)司股東的扣除非經常(chang)性(xing)損益的凈(jing)利潤(run)13.04億(yi)(yi)元，同(tong)(tong)比(bi)(bi)分別增長(chang)13.10%和11.71%。